Agenus — Third Quarter 2026 Earnings Summary

Agenus reported third-quarter 2026 results featuring $31.5 million in total revenue and $11.4 million in operating income, marking the third consecutive quarter of positive operating income. The company secured its first global marketing authorizations for the combination of botensilimab and balstilimab in Armenia for treating metastatic colorectal cancer. Clinical data from the NEST and UNICORN studies demonstrated approximately 30% pathologic complete response rates in microsatellite-stable colon cancer patients treated with the combination therapy prior to surgery. Additionally, the ROBBIN Phase 3 trial is on track for first patient enrollment in the first quarter of 2027, supported by $86.9 million in cash and financing that extends through 2031.